Related Experiment Videos
Regulation of cell proliferation using tissue engineering in MIN6 cells
N Kinoshita1, Y Echigo, S Shinohara
1Department of Organ Reconstruction, Institute for Frontier Medical Sciences, Kyoto University, Japan. naok@frontier.kyoto-u.ac.jp
Abstract:
Pancreatic islet transplantation for patients with diabetes mellitus has been hindered by the problem of donor shortage, as is the case for transplantation of other organs. Among several measures to overcome this problem, cell transplantation using xenogenic cell lines has been considered. For the treatment of diabetic patients, a murine pancreatic beta-cell line MIN6 is a potential source of cell transplant. In order to restrict otherwise unlimited proliferation of transplanted MIN6 cells, cells are rendered to form spheroidal aggregates (SMIN6) on nonadherent culture dishes. SMIN6 stopped its growth around day 7 with a diameter of 220 +/- 40 microm and kept its size almost constant at least until day 28. SMIN6 cells, however, had reduced responsiveness of insulin secretion to glucose concentration compared with MIN6 cells cultured in a monolayer. On the other hand, spheroid MIN6 cells formed in the presence of extracellular matrix gel (SMIN6E) possessed the capacity for glucose-dependent insulin secretion comparable with conventional MIN6 cells. SMIN6E encapsulated in agarose beads (SMIN6E-B) was also viable for at least 1 month in vitro with a constant diameter and favorable glucose responsiveness. The development of spheroid-type MIN6 may contribute to the future clinical application of MIN6 or other beta-cell lines for treatment of diabetes mellitus.
Insights
To address donor shortages for diabetes treatment, researchers developed spheroid MIN6 (SMIN6) cells. Modified SMIN6 cells with extracellular matrix gel (SMIN6E) show promise for glucose-dependent insulin secretion, potentially aiding future cell transplantation therapies.
Area of Science:
- Biotechnology
- Endocrinology
- Regenerative Medicine
Background:
- Pancreatic islet transplantation for diabetes mellitus faces donor organ shortages.
- Xenogenic cell lines, like murine MIN6 beta-cells, are explored as alternatives.
- Controlling proliferation of transplanted cells is crucial for safety and efficacy.
Purpose of the Study:
- To develop strategies for limiting the proliferation of transplanted MIN6 cells.
- To evaluate the functional capacity of modified MIN6 cell aggregates for diabetes treatment.
- To assess the viability and glucose responsiveness of encapsulated MIN6 spheroids.
Main Methods:
- MIN6 cells were cultured as spheroids (SMIN6) on nonadherent dishes to control proliferation.
- SMIN6 cells were further modified with extracellular matrix gel (SMIN6E).
- SMIN6E cells were encapsulated in agarose beads (SMIN6E-B) for in vitro assessment.
Main Results:
- SMIN6 spheroids ceased proliferation around day 7 and maintained size for at least 28 days.
- Standard SMIN6 spheroids exhibited reduced glucose-stimulated insulin secretion compared to monolayer cultures.
- SMIN6E spheroids demonstrated glucose-dependent insulin secretion comparable to conventional MIN6 cells.
- SMIN6E-B constructs remained viable for over a month with stable size and good glucose responsiveness.
Conclusions:
- Spheroid formation effectively controls MIN6 cell proliferation.
- Incorporating extracellular matrix gel enhances glucose responsiveness in MIN6 spheroids.
- Agarose encapsulation maintains viability and function of MIN6 spheroids.
- Spheroid-type MIN6 cells represent a promising avenue for future clinical applications in diabetes mellitus treatment.